Department of Biological Sciences, Pusan National University, Pusan, 46241, Republic of Korea.
Genes Genomics. 2020 May;42(5):543-551. doi: 10.1007/s13258-020-00922-y. Epub 2020 Mar 23.
Previous studies have shown that the copy number of microRNA (miR)-124 is decreased in diffuse large B cell lymphoma (DLBCL), and that miR-124 is a tumor suppressor by targeting NF-κB p65 in B-cell lymphoma. In turn, miR-124 expression is regulated by transcription factors such as HNF4α, ETS2, and p53. However, whether and how miR-124 transcription is modulated by NF-κB transcription factors remain unknown in DLBCL.
To investigate whether the activation of NF-κB signaling could inhibit the expression of miR-124, possibly contributing to the pathogenesis of DLBCL.
Potential transcription factors regulating miR-124 transcription were predicted using the Transfac software. The cellular effects of NF-κB p65 on miR-124 were examined by MTS assay, Western blot assay, qPCR, and chromatin immunoprecipitation (ChIP) assays using DLBCL cell lines.
Inhibition of NF-κB signals using Bay11-7085 increased miR-124 expression whereas exposure to TNF-α decreased it. Ectopic expression of p65 suppressed miR-124 expression, suggesting that p65 may be a transcriptional repressor of miRNA-124. Pharmacological analyses showed that phosphorylated/activated p65 downregulates miR-124 via two signaling pathways: (1) TAK1/IKKα-IKKβ/IκBα and (2) MAPK/p65. Moreover, ChIP assay demonstrated that p65 directly regulates miR-124 by binding to the NF-κB consensus sequence in its promoter region. Finally, we also confirmed that stable ectopic expression of miR-124 suppresses cell proliferation and survival.
Taken together, our study uncovered a mechanism by which active NF-κB signaling disrupts the function of miR-124 as a tumor suppressor in DLBCL.
先前的研究表明,微 RNA(miR)-124 的拷贝数在弥漫性大 B 细胞淋巴瘤(DLBCL)中降低,并且 miR-124 通过靶向 B 细胞淋巴瘤中的 NF-κB p65 作为肿瘤抑制因子。反过来,miR-124 的表达受转录因子(如 HNF4α、ETS2 和 p53)的调节。然而,NF-κB 转录因子是否以及如何调节 miR-124 的转录在 DLBCL 中仍然未知。
研究 NF-κB 信号的激活是否可以抑制 miR-124 的表达,这可能有助于 DLBCL 的发病机制。
使用 Transfac 软件预测调节 miR-124 转录的潜在转录因子。使用 DLBCL 细胞系通过 MTS 测定、Western blot 测定、qPCR 和染色质免疫沉淀(ChIP)测定来研究 NF-κB p65 对 miR-124 的细胞效应。
使用 Bay11-7085 抑制 NF-κB 信号会增加 miR-124 的表达,而暴露于 TNF-α 会降低其表达。p65 的异位表达抑制了 miR-124 的表达,表明 p65 可能是 miRNA-124 的转录抑制子。药理分析表明,磷酸化/激活的 p65 通过两条信号通路下调 miR-124:(1)TAK1/IKKα-IKKβ/IκBα 和(2)MAPK/p65。此外,ChIP 测定表明,p65 通过与启动子区域中的 NF-κB 共有序列结合直接调节 miR-124。最后,我们还证实,miR-124 的稳定异位表达抑制了细胞增殖和存活。
总之,我们的研究揭示了一种机制,即活性 NF-κB 信号破坏了 miR-124 在 DLBCL 中作为肿瘤抑制因子的功能。